{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T07:01:01Z","timestamp":1777100461291,"version":"3.51.4"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000072","name":"National Institute of Dental and Craniofacial Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000072","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.taap.2014.06.010","type":"journal-article","created":{"date-parts":[[2014,6,24]],"date-time":"2014-06-24T11:34:25Z","timestamp":1403609665000},"page":"220-229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Comparative toxicity and efficacy of engineered anthrax lethal toxin variants with broad anti-tumor activities"],"prefix":"10.1016","volume":"279","author":[{"given":"Diane E.","family":"Peters","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Hoover","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loretta Grey","family":"Cloud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shihui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo A.","family":"Molinolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen H.","family":"Leppla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas H.","family":"Bugge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2014.06.010_bb0175","doi-asserted-by":"crossref","first-page":"7437","DOI":"10.1158\/1078-0432.CCR-06-2019","article-title":"Systemic anthrax lethal toxin therapy produces regressions of subcutaneous human melanoma tumors in athymic nude mice","volume":"12","author":"Abi-Habib","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.taap.2014.06.010_bb0130","doi-asserted-by":"crossref","first-page":"745","DOI":"10.4161\/cc.7.6.5627","article-title":"Potent inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin: implications for broad anti-tumor efficacy","volume":"7","author":"Alfano","year":"2008","journal-title":"Cell Cycle"},{"key":"10.1016\/j.taap.2014.06.010_bb0095","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1158\/1535-7163.MCT-09-0694","article-title":"Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma","volume":"9","author":"Alfano","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.taap.2014.06.010_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z","article-title":"The urokinase-type plasminogen activator system in cancer metastasis: a review","volume":"72","author":"Andreasen","year":"1997","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.taap.2014.06.010_bb0050","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/n35101999","article-title":"Identification of the cellular receptor for anthrax toxin","volume":"414","author":"Bradley","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.taap.2014.06.010_bb0010","series-title":"Head and Neck Cancer","first-page":"137","article-title":"Proteolysis in carcinogenesis","author":"Bugge","year":"2003"},{"key":"10.1016\/j.taap.2014.06.010_bb0160","doi-asserted-by":"crossref","first-page":"R699","DOI":"10.1152\/ajpregu.00593.2003","article-title":"Lethality during continuous anthrax lethal toxin infusion is associated with circulatory shock but not inflammatory cytokine or nitric oxide release in rats","volume":"286","author":"Cui","year":"2004","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.taap.2014.06.010_bb0070","doi-asserted-by":"crossref","first-page":"7049","DOI":"10.1073\/pnas.062160399","article-title":"Mapping the lethal factor and edema factor binding sites on oligomeric anthrax protective antigen","volume":"99","author":"Cunningham","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.taap.2014.06.010_bb0080","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1126\/science.280.5364.734","article-title":"Proteolytic inactivation of MAP-kinase\u2013kinase by anthrax lethal factor","volume":"280","author":"Duesbery","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.taap.2014.06.010_bb0015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1559-0275-8-9","article-title":"The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?","volume":"8","author":"Duffy","year":"2011","journal-title":"Clin. Proteomics"},{"key":"10.1016\/j.taap.2014.06.010_bb0180","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.4049\/jimmunol.1002471","article-title":"Neutrophil elastase mediates pathogenic effects of anthrax lethal toxin in the murine intestinal tract","volume":"185","author":"Fang","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.taap.2014.06.010_bb0165","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.2741\/3382","article-title":"Anthrax toxin: pathologic effects on the cardiovascular system","volume":"14","author":"Golden","year":"2009","journal-title":"Front. Biosci."},{"key":"10.1016\/j.taap.2014.06.010_bb0155","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0955-0674(98)80044-6","article-title":"Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation","volume":"10","author":"Johnsen","year":"1998","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.taap.2014.06.010_bb0065","doi-asserted-by":"crossref","first-page":"10277","DOI":"10.1073\/pnas.89.21.10277","article-title":"Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin","volume":"89","author":"Klimpel","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.taap.2014.06.010_bb0135","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1111\/j.1365-2958.1994.tb00500.x","article-title":"Anthrax toxin lethal factor contains a zinc metalloprotease consensus sequence which is required for lethal toxin activity","volume":"13","author":"Klimpel","year":"1994","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.taap.2014.06.010_bb0020","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1515\/cclm-2012-0247","article-title":"Kallikrein-related peptidases (KLKs): a gene family of novel cancer biomarkers","volume":"50","author":"Kontos","year":"2012","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.taap.2014.06.010_bb0030","first-page":"6061","article-title":"Tumor cell-selective cytotoxicity of matrix metalloproteinase-activated anthrax toxin","volume":"60","author":"Liu","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.taap.2014.06.010_bb0035","doi-asserted-by":"crossref","first-page":"17976","DOI":"10.1074\/jbc.M011085200","article-title":"Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin","volume":"276","author":"Liu","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.taap.2014.06.010_bb0045","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1517\/14712598.3.5.843","article-title":"Anthrax toxin: structures, functions and tumour targeting","volume":"3","author":"Liu","year":"2003","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.taap.2014.06.010_bb0100","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1073\/pnas.0236849100","article-title":"Potent antitumor activity of a urokinase-activated engineered anthrax toxin","volume":"100","author":"Liu","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.taap.2014.06.010_bb0040","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/nbt1091","article-title":"Intermolecular complementation achieves high-specificity tumor targeting by anthrax toxin","volume":"23","author":"Liu","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.taap.2014.06.010_bb0105","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1074\/jbc.M707419200","article-title":"Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature","volume":"283","author":"Liu","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.taap.2014.06.010_bb0055","doi-asserted-by":"crossref","first-page":"12424","DOI":"10.1073\/pnas.0905409106","article-title":"Capillary morphogenesis protein-2 is the major receptor mediating lethality of anthrax toxin in vivo","volume":"106","author":"Liu","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.taap.2014.06.010_bb0170","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/nature12510","article-title":"Key tissue targets responsible for anthrax-toxin-induced lethality","volume":"501","author":"Liu","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.taap.2014.06.010_bb0185","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1172\/JCI17991","article-title":"Bacillus anthracis lethal toxin induces TNF-alpha-independent hypoxia-mediated toxicity in mice","volume":"112","author":"Moayeri","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.taap.2014.06.010_bb0075","doi-asserted-by":"crossref","first-page":"7045","DOI":"10.1073\/pnas.052160199","article-title":"The lethal and edema factors of anthrax toxin bind only to oligomeric forms of the protective antigen","volume":"99","author":"Mogridge","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.taap.2014.06.010_bb0190","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1128\/IAI.00963-10","article-title":"MyD88-dependent signaling protects against anthrax lethal toxin-induced impairment of intestinal barrier function","volume":"79","author":"Okugawa","year":"2011","journal-title":"Infect. Immun."},{"key":"10.1016\/j.taap.2014.06.010_bb0150","first-page":"1","article-title":"B16 as a mouse model for human melanoma","author":"Overwijk","year":"2001","journal-title":"Curr. Protoc. Immunol."},{"key":"10.1016\/j.taap.2014.06.010_bb0140","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1006\/prep.2000.1208","article-title":"Optimized production and purification of Bacillus anthracis lethal factor","volume":"18","author":"Park","year":"2000","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.taap.2014.06.010_bb0110","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1158\/1535-7163.MCT-05-0163","article-title":"Antitumor efficacy of a urokinase activation-dependent anthrax toxin","volume":"5","author":"Rono","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.taap.2014.06.010_bb0025","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.1200\/JCO.2009.23.5556","article-title":"Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer","volume":"27","author":"Roy","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.taap.2014.06.010_bb0115","doi-asserted-by":"crossref","first-page":"e20532","DOI":"10.1371\/journal.pone.0020532","article-title":"Efficient targeting of head and neck squamous cell carcinoma by systemic administration of a dual uPA and MMP-activated engineered anthrax toxin","volume":"6","author":"Schafer","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.taap.2014.06.010_bb0060","doi-asserted-by":"crossref","first-page":"5170","DOI":"10.1073\/pnas.0431098100","article-title":"Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor","volume":"100","author":"Scobie","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.taap.2014.06.010_bb0120","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1158\/0008-5472.CAN-06-4642","article-title":"Systematic urokinase-activated anthrax toxin therapy produces regressions of subcutaneous human non-small cell lung tumor in athymic nude mice","volume":"67","author":"Su","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.taap.2014.06.010_bb0195","doi-asserted-by":"crossref","first-page":"e33583","DOI":"10.1371\/journal.pone.0033583","article-title":"Anthrax lethal toxin disrupts intestinal barrier function and causes systemic infections with enteric bacteria","volume":"7","author":"Sun","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.taap.2014.06.010_bb0145","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/BF00300234","article-title":"Determination of subcutaneous tumor size in athymic (nude) mice","volume":"24","author":"Tomayko","year":"1989","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.taap.2014.06.010_bb0085","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1006\/bbrc.1998.9040","article-title":"Anthrax lethal factor cleaves the N-terminus of MAPKKs and induces tyrosine\/threonine phosphorylation of MAPKs in cultured macrophages","volume":"248","author":"Vitale","year":"1998","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"Pt 3","key":"10.1016\/j.taap.2014.06.010_bb0090","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1042\/bj3520739","article-title":"Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor","volume":"352","author":"Vitale","year":"2000","journal-title":"Biochem. J."},{"key":"10.1016\/j.taap.2014.06.010_bb0125","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s10637-012-9847-1","article-title":"Tumor therapy with a urokinase plasminogen activator-activated anthrax lethal toxin alone and in combination with paclitaxel","volume":"31","author":"Wein","year":"2013","journal-title":"Investig. New Drugs"}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X14002336?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X14002336?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T20:43:12Z","timestamp":1758573792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X14002336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0041008X14002336"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2014.06.010","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative toxicity and efficacy of engineered anthrax lethal toxin variants with broad anti-tumor activities","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2014.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}